Abstract:The transforming growth factor-beta (TGF-β) inhibits the growth of most epithelial and hematopoietic cells. The activity of the TGF-β-initiated signaling pathways is under tight control by processes including regulation of tumor suppressor SMAD proteins. TGF-β signaling is generally mediated through intracellular signal transducers and transcription factors called SMADs. Deregulation of TGF-β signaling contributes to pathogenesis of many diseases including cancer, fibrotic diseases, and vascular diseases. Loss of the TGF-β antiproliferative response is a hallmark in human cancer. However, genetic mutations in SMADs or TGF-β receptors are rare in immune system-derived cancers. Thus, the mechanisms underlying TGF-β resistance in lymphoma or leukemia are largely elusive. Objective: To elucidate the mechanisms underlying TGF-β resistance in B-cell lymphoma. Methods: Using protein array-based approach, we identified oncoproteins BCL6 as an interacting protein of tumor suppressor SMAD4. We further validated the BCL6-SMAD4 physical interaction by biochemical assays such as immunoprecipitation and in vitro binding assay. Transcriptional assays were used to assess the ability of BCL6 to repress the activity of SMAD4 as a transcription factor. DNA synthesis rate was assayed by 3H-thymidine incorporation in Burkitt-like lymphoma cell lines BL41, BJAB, Ramos, Daudi, and Raji. BCL6 expression was analyzed by Western blotting. BCL6 expression was knocked down in BJAB cells using siRNA. The binding of BCL6 to the TGF-β-responsive gene promoter was analyzed by chromatin immunoprecipitation. Results: The level of BCL6 was significantly higher in all B-cell lymphoma cell lines except BL41. These B-cell lymphoma cells with a high expression level of BCL6 were found to be refractory to TGF-β antiproliferative response, whereas BL41 cells underwent TGF-β-mediated growth inhibition. Knockdown of BCL6 could restore the TGF-β sensitivity in TGF-β resistant cells. Meanwhile, we have identified the oncoprotein BCL6 as a transcriptional corepressor of tumor suppressor SMAD4. BCL6 physically interacted with SMAD4, occupied the gene promoter of TGF-β target genes, disrupted the SMAD4-p300 interaction. Consequently, BCL6 repressed the transcriptional activity of SMAD4 and blocked the expression TGF-β-induced anti-proliferation factors. Conclusion: Our study provides compelling evidence that overexpression of BCL6, that often occurs in B-cell lymphoma, contributes to TGF-β resistance. Thus, our finding should provide insights into the mechanism of TGF-β anti-cancer actions. Knowledge gained from these studies will be used to design novel therapeutic strategies for prevention and treatment of human cancer.

Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation

The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation

Epigenetic Inactivation of Bcl6b, A Novel Functional Tumour Suppressor for Gastric Cancer, is Associated with Poor Survival

High BCL6 Expression Predicts Better Prognosis, Independent of BCL6 Translocation Status, Translocation Partner, or BCL6-deregulating Mutations, in Gastric Lymphoma.

A Conserved Regulator of Immunity and Beyond

The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target

The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

The F-box E3 ligase protein FBXO11 regulates EBNA3C-associated degradation of BCL6

CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis

BCL-6 negatively regulates expression of the NF-kappaB1 p105/p50 subunit

Bcl6 Represses Smad Signaling in Transforming Growth Factor-Beta Resistance

B-cell lymphoma 6 protein stimulates oncogenicity of human breast cancer cells

The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress

The Oncoprotein BCL6 Enables Cancer Cells to Evade Genotoxic Stress

Super-enhancer hypermutation alters oncogene expression in B cell lymphoma

The Human Bcl6 Transgene Promotes The Development Of Lymphomas In The Mouse

The Relationship between RUVBL1 (Pontin, TIP49, NMP238) and BCL6 in Benign and Malignant Human Lymphoid Tissues

Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL)

Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis

Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond

50. Oncogene BCL6 Antagonizes Tumor Suppressor SMAD4 to Cause TGF-β Resistance